Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and ...

India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics , a U.S.-based immunotherapy and targeted oncology company, for $355 million.

Sun Pharmaceutical Industries announces acquisition of US-based Checkpoint Therapeutics for up to USD 355 million. The Indian ...

Sun Pharmaceutical Industries Ltd. closed 15.54% short of its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.

Sun Pharma has acquired Checkpoint Therapeutics for $355 million, enhancing its onco-dermatology portfolio with the ...

While the brokerage remains positive on the growth outlook for Sun’s key specialty brands (Ilumya, Winlevi, and Cequa), it noted some delays in clinical trials for pipeline assets. However ...

Sun Pharma, India's largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This ...

Sun Pharmaceutical Industries Ltd. 524715 shares inched down 0.26% to 1,609.90 Indian rupees Friday, on what proved to be an all-around poor trading session for the stock market, with the BSE ...

Sun Pharma Advanced Research Company Ltd share price was up by 8.37% from the previous closing price of ₹126.05. Who are peers of Sun Pharma Advanced Research Company Ltd? The peers of Sun ...

BENGALURU (Reuters) -India's drug regulator has found more than 50 drugs, including some batches of widely used antacids and paracetamol, to be substandard or fake, according to government documents.

A US district court has granted an injunction sought by Incyte on the launch of Sun Pharma's recently approved Leqselvi for alopecia areata. In a brief filing with the National Stock Exchange (NSE ...

Sun Pharma is a top-ranked Indian pharmaceutical firm. The company’s stock has been continuously in the news lately for walking on the thin line of marketplace volatility, governmental regulations, ...